Basilea Pharmaceutica AG

BATS-CHIXE:BSLNz Stock Report

Market Cap: CHF 493.3m

Basilea Pharmaceutica Valuation

Is BSLNz undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BSLNz when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CHF 38.33
Fair Value
6.6% overvalued intrinsic discount
6
Number of Analysts

Below Fair Value: BSLNz (CHF40.85) is trading above our estimate of fair value (CHF38.33)

Significantly Below Fair Value: BSLNz is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BSLNz?

Key metric: As BSLNz is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BSLNz. This is calculated by dividing BSLNz's market cap by their current revenue.
What is BSLNz's PS Ratio?
PS Ratio3.3x
SalesCHF 149.02m
Market CapCHF 493.33m

Price to Sales Ratio vs Peers

How does BSLNz's PS Ratio compare to its peers?

The above table shows the PS ratio for BSLNz vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.5x
OXB Oxford Biomedica
4.5x21.2%UK£441.8m
BVXP Bioventix
11.9xn/aUK£161.8m
GNS Genus
1.9x3.5%UK£1.3b
AVCT Avacta Group
7.7x0.4%UK£173.8m
BSLNz Basilea Pharmaceutica
3.3x2.8%CHF 493.3m

Price-To-Sales vs Peers: BSLNz is good value based on its Price-To-Sales Ratio (3.3x) compared to the peer average (6.5x).

Price to Sales Ratio vs Industry

How does BSLNz's PS Ratio compare vs other companies in the GB Biotechs Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.n/a15.9%
BSLNz Basilea Pharmaceutica
 3.3x2.8%US$541.69m
GNS Genus
1.9x3.5%US$1.58b
OXB Oxford Biomedica
4.5x21.2%US$547.84m
No. of Companies7PS020406080100+
8 CompaniesEstimated GrowthMarket Cap
Industry Avg.n/a38.6%
BSLNz Basilea Pharmaceutica
 3.3x14.9%US$541.69m
No more companies

Price-To-Sales vs Industry: BSLNz is good value based on its Price-To-Sales Ratio (3.3x) compared to the European Biotechs industry average (8.4x).

Price to Sales Ratio vs Fair Ratio

What is BSLNz's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BSLNz PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.3x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: BSLNz is expensive based on its Price-To-Sales Ratio (3.3x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BSLNz forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 40.85
CHF 77.25
+89.1%
31.6%CHF 120.00CHF 52.00n/a6
Jan ’26CHF 41.35
CHF 77.25
+86.8%
31.6%CHF 120.00CHF 52.00n/a6
Dec ’25CHF 41.65
CHF 77.25
+85.5%
31.6%CHF 120.00CHF 52.00n/a6
Nov ’25CHF 43.48
CHF 74.87
+72.2%
35.7%CHF 120.00CHF 44.20n/a6
Oct ’25CHF 45.45
CHF 73.20
+61.1%
32.8%CHF 110.00CHF 44.20n/a6
Sep ’25CHF 46.10
CHF 72.37
+57.0%
32.0%CHF 110.00CHF 44.20n/a6
Aug ’25CHF 39.80
CHF 71.20
+78.9%
30.5%CHF 105.00CHF 44.20n/a6
Jul ’25CHF 39.30
CHF 71.20
+81.2%
30.5%CHF 105.00CHF 44.20n/a6
Jun ’25CHF 43.80
CHF 70.58
+61.1%
31.9%CHF 105.00CHF 40.50n/a6
May ’25CHF 39.65
CHF 70.58
+78.0%
31.9%CHF 105.00CHF 40.50n/a6
Apr ’25CHF 37.63
CHF 69.08
+83.6%
30.6%CHF 105.00CHF 40.50n/a6
Mar ’25CHF 35.10
CHF 69.08
+96.8%
30.6%CHF 105.00CHF 40.50n/a6
Feb ’25CHF 33.00
CHF 64.38
+95.1%
24.7%CHF 85.00CHF 40.50CHF 40.854
Jan ’25CHF 35.40
CHF 70.70
+99.7%
26.5%CHF 91.00CHF 40.50CHF 41.355
Dec ’24CHF 34.70
CHF 75.68
+118.1%
19.8%CHF 91.00CHF 57.70CHF 41.654
Nov ’24CHF 35.45
CHF 73.28
+106.7%
20.1%CHF 91.00CHF 52.00CHF 43.486
Oct ’24CHF 40.90
CHF 70.44
+72.2%
21.7%CHF 91.00CHF 52.00CHF 45.457
Sep ’24CHF 47.90
CHF 70.44
+47.1%
21.7%CHF 91.00CHF 52.00CHF 46.107
Aug ’24CHF 43.70
CHF 70.44
+61.2%
21.7%CHF 91.00CHF 52.00CHF 39.807
Jul ’24CHF 41.85
CHF 67.18
+60.5%
21.0%CHF 91.00CHF 52.00CHF 39.306
Jun ’24CHF 45.60
CHF 67.18
+47.3%
21.0%CHF 91.00CHF 52.00CHF 43.806
May ’24CHF 43.30
CHF 72.07
+66.4%
20.8%CHF 91.00CHF 52.00CHF 39.656
Apr ’24CHF 50.20
CHF 74.80
+49.0%
18.4%CHF 91.00CHF 52.00CHF 37.635
Mar ’24CHF 52.30
CHF 68.98
+31.9%
26.2%CHF 91.00CHF 39.90CHF 35.106
Feb ’24CHF 48.85
CHF 73.82
+51.1%
34.7%CHF 120.00CHF 39.90CHF 33.006
Analyst Price Target
Consensus Narrative from 6 Analysts
CHF 77.53
Fair Value
47.3% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/03 08:36
End of Day Share Price 2025/01/31 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Basilea Pharmaceutica AG is covered by 25 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leonildo DelgadoBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Markus MayerBaader Helvea Equity Research